Developing Psychedelic Therapies for Addiction
We are developing evidence-based, patent-protected, synthetically-derived psychedelic therapeutics to transform the treatment of addiction, starting with synthetic Mescaline HCl (JOUR-5700) for the treatment of alcohol use disorder.
Journey Colab is a biopharmaceutical company unlocking the science of psychedelics
Our mission is to unlock the promising science behind psychedelics to provide durable remission to patients suffering from addiction
Backed by world class investors
We believe that delivering effective psychedelic treatments for addiction and other mental health disorders will also require medicine-induced behavioral modification therapy and community support.
Our long-term vision includes not just effective psychedelic products but also enabling a healing economy that includes on-the-ground specialists and the infrastructure that supports their work.
Journey Colab is developing psychedelic solutions for the treatment of addiction and other mental health disorders, starting with Mescaline HCl (JOUR-5700) for patients with Alcohol Use Disorder (AUD), who are in desperate need of durable remission from this chronic, relapsing condition.
Americans suffer from addiction today. Only 10% receive lasting benefit from current treatments. ~75% of substance use cases are alcohol-related.
in estimated annual expenditure in U.S. on SUD (2020)
of adults with SUD don’t get treatment
in the estimated economic burden in the U.S. from SUD (2022)
Built with Reciprocity in Mind
Through our unique stakeholder structure, we have built an experienced team dedicated to our mission of creating scientifically rigorous and clinically validated treatments and improving equitable access to care. Ten percent of our founding equity is dedicated to sharing success with stakeholders to increase equitable access to care and recruit employees and partnerships.
Get Our Primer
As a result of seeing increased interest in the psychedelics space, we put together a primer (created by Anna Martirosyan, our Head of Special Projects) to give funds, limited partners, and others an overview of the market.
If you're interested in viewing the primer or learning more,
please reach out to us.
We're here to build an ecosystem and we will need people from all sides and walks of life to get involved in this brave new world and healing economy we're building.